On November 5, Zoetis broke ground on a new manufacturing facility in Suzhou, China. The site will produce animal medications for China and supply products for livestock customers in more than 60 countries. It will replace the company’s current Global Manufacturing & Supply operations in the city in 2018.

Stefan Weiskopf, Zoetis executive vice president and area president, Asia Pacific, hosted a formal groundbreaking ceremony to mark the event in early November and was joined by Chuck Schneider, vice president of Asia Pacific operations, global manufacturing and supply.

"The work delivered here, and at our other 25-plus manufacturing sites globally, enables us to deliver on the company's overall mission to bring our customers quality products, services, and a commitment to their business,” Dr. Weiskopf said.

Mr. Schneider added, “The products we will manufacture here will have a global reach. They will touch customers in many ways and contribute to the health, safety and productivity of livestock around the world.”

Suzhou will be the manufacturing hub for the production of pre-mix and soluble powder products. Notable products include Lincomix®, Linco-spectin® and Neomix®, which are feed medicine products.

Zoetis began operations in China in 1995 and now has more than 560 colleagues. The business moved its headquarters from Beijing to Shanghai in 1998.  Zoetis China has R&D located in Shanghai and manufacturing operations located in several locations including Suzhou, Shenzhou, and Yantai. The Zoetis joint venture with Jilin Guoyuan Animal Health Company has its commercial and manufacturing site located Changchun. In China, Zoetis has registered and launched a series of products for swine, dairy cattle, poultry and companion animals, including vaccines, antibiotics, parasiticides and anti-infectives.